AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia

AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R44CA221539-01
Agency Tracking Number: R44CA221539
Amount: $1,867,190.00
Phase: Phase II
Program: SBIR
Awards Year: 2017
Solicitation Year: 2014
Solicitation Topic Code: 102
Solicitation Number: PAR14-088
Small Business Information
13420 GLEN LEA WAY, Rockville, MD, 20850-3638
DUNS: 079995027
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 BUEL RODGERS
 (208) 596-9807
 danrodgers@aavogen.com
Business Contact
 BUEL RODGERS
Phone: (208) 596-9807
Email: danrodgers@aavogen.com
Research Institution
N/A
Abstract
PROJECT SUMMARYThe skeletal muscle wasting that occurs with cancer cachexia compromises quality of life and is both directly and indirectly responsible for cancer mortalitiesTumor derived and tumor responsive factors as well as many therapeutics themselves contribute to the cachectic statealthough nutritional support has little if any positive effect on restoring striated muscle mass or functionThusnovel tools for preventing muscle wasting in cancer patients could transform their treatment and significantly improve their quality of lifeOur research objective is to test a novel gene therapeutic for enhancing muscle regeneration in a mouse model of tumorand chemotherapy induced cachexia and in additionto complete the GLP toxicology studies required for IND filingWe hypothesize that attenuating the intracellular signaling pathways responsible for muscle atrophy and impaired muscle regeneration will in turn restore muscle mass and function and significantly delay mortalityIn factPhase I equivalent data indicate that attenuating ActRIIB and Smadsignaling with rAAVSmada k aAVGNsignificantly enhances muscle mass and function in wild type mice and can completely prevent muscle atrophy in different mouse models of cancer cachexiaMost importantlythis therapeutic does not produce the serious off target effects that have compromised development of competing technologies that have either been shown to compromise blood vessel integrity or to possess this potentialOur specific aims are toitest the hypothesis that rAAVSmadcan prevent cancerand chemotherapyinduced muscle wastingiitest the hypothesis that rAAVSmadreduces cancer mortality andiiicomplete murine and non human primate toxicology studies with rAAVSmadThe proposed approach is truly innovative as it utilizes a novel gene therapeutic and state of the art tools to comprehensively assess muscle function at different scalesThese studies are also highly significant as they will provide a better mechanistic understanding of how tumorand chemotherapy induced muscle wasting are independently affected by ActRIIB and SmadsignalingMost importantlythese translational studies have the very real potential to impact clinical medicine and to advance clinical trials of rAAVSmad

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government